{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:14:43Z","timestamp":1774430083035,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Eisai Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.eplepsyres.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T08:05:17Z","timestamp":1470384317000},"page":"201-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study"],"prefix":"10.1016","volume":"126","author":[{"given":"V.","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Rodriguez-Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gonz\u00e1lez-Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Serratosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gonz\u00e1lez-Gir\u00e1ldez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Suller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rodr\u00edguez-Uranga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Saiz-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gonz\u00e1lez-de la Aleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"L\u00f3pez-Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Poza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2826-3374","authenticated-orcid":false,"given":"J.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Querol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Giner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Molins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-9318","authenticated-orcid":false,"given":"P.","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Baiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/epd.2010.0303","article-title":"The evolution of antiepileptic drug development and regulation","volume":"12","author":"Arzimanoglou","year":"2010","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"Bancaud","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs \u2013 rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jnnp-2013-307074","article-title":"Increased mortality persists in an adult drug-resistant epilepsy prevalence cohort","volume":"85","author":"Callaghan","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0030","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J. Psychiatr Res."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yebeh.2014.09.072","article-title":"Clinical experience with perampanel: focus on psychiatric adverse effects","volume":"41","author":"Coyle","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0040","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0045","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eplepsyres.2014.12.001","article-title":"Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy","volume":"110","author":"Gao","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0065","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0070","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/11631540-000000000-00000","article-title":"Management of seizures following a stroke: what are the options?","volume":"29","author":"Gilad","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0080","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl. P1","key":"10.1016\/j.eplepsyres.2016.08.001_bib0085","first-page":"255","article-title":"Pharmacokinetic, pharmacodynamic and cognitive effects of adjunctive perampanel in adolescents with inadequately controlled partial seizures","volume":"84","author":"Hussein","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2005.05.005","article-title":"Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study","volume":"65","author":"Knoester","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0095","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0105","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0115","first-page":"231","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials","author":"Laurenza","year":"2012","journal-title":"Epilepsy Curr.\/Am. Epilepsy Soc."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eplepsyres.2014.11.015","article-title":"Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials","volume":"110","author":"Leppik","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.yebeh.2009.07.013","article-title":"Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques","volume":"16","author":"Richy","year":"2009","journal-title":"Epilepsy Behav."},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2016.08.001_bib0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/epi.12182","article-title":"The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs","volume":"54","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.yebeh.2010.08.011","article-title":"Changes in seizure severity and quality of life in patients with refractory partial epilepsy","volume":"19","author":"Sancho","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1535-7511.2008.01289.x","article-title":"New developments in antiepileptic drug resistance: an integrative view","volume":"9","author":"Schmidt","year":"2009","journal-title":"Epilepsy Curr.\/Am. Epilepsy Soc."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2015.10.017","article-title":"Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study","volume":"34","author":"Shah","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0155","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0160","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eplepsyres.2014.03.015","article-title":"A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria","volume":"108","author":"Steinhoff","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0165","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(08)70202-3","article-title":"Sudden unexpected death in epilepsy: current knowledge and future directions","volume":"7","author":"Tomson","year":"2008","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0175","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/epi.13019","article-title":"Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures","volume":"56","author":"Vazquez","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nrl.2012.04.012","article-title":"Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study","volume":"28","author":"Villanueva","year":"2013","journal-title":"Neurolog\u00eda (Barcelona, Spain)"},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2016.08.001_bib0190","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res."}],"updated-by":[{"DOI":"10.1016\/j.eplepsyres.2016.12.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000}}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116301218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116301218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:36:54Z","timestamp":1760276214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121116301218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"alternative-id":["S0920121116301218"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.08.001","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.eplepsyres.2016.12.005","asserted-by":"object"}]},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}